On an annual basis, the company posted revenue of KRW 20.27 billion and operating profit of KRW 1.80 billion (an 8.9% operating margin) in 2022, but profit shrank in 2023 to revenue of KRW 15.97 billion and operating profit of KRW 0.39 billion (a 2.5% margin), before revenue fell further to KRW 9.45 billion in 2024 alongside an operating loss of KRW 4.40 billion (a -46.5% margin).
In 2025, revenue recovered somewhat to KRW 11.46 billion, yet the operating loss widened to KRW 5.05 billion (a -44.0% margin).
Net income attributable to owners followed a similar pattern, swinging from profits of KRW 1.77 billion in 2022 and KRW 1.56 billion in 2023 to losses of KRW 20.85 billion in 2024 and KRW 21.92 billion in 2025.
Quarterly, revenue was KRW 1.39 billion with an operating loss of KRW 1.75 billion and a net loss of KRW 3.52 billion in the second quarter of 2025, followed by revenue of KRW 1.91 billion, an operating loss of KRW 1.45 billion, and a net loss of KRW 2.17 billion in the third quarter.
Fourth-quarter 2025 results have not yet been finalized in disclosures.
Revenue then surged to KRW 11.33 billion and KRW 14.11 billion in the first and second quarters of 2026, respectively, though operating losses of KRW 4.24 billion and KRW 3.35 billion continued, with the second-quarter net loss widening sharply to KRW 10.67 billion.
This dramatic swing in revenue scale appears largely attributable to the consolidation effect of subsidiary Vitro, while the core inspection equipment business alone continues to operate at an operating loss.
On the 2025 balance sheet, the debt ratio jumped from 37.0% the prior year to 185.5%, driven by the newly recognized non-controlling interest of KRW 12.74 billion and total liabilities rising sharply from KRW 13.89 billion to KRW 84.59 billion.